Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7106MR)

This product GTTS-WQ7106MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7106MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1088MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ9785MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ6887MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ8441MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ4471MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ13766MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ701MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ9094MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW